Phase II Study results of trabectedin combined with low-dose radiation therapy for Soft Tissue Sarcoma are presented at ESMO

On September 30, 2019 Sarcoma Research Groups in Spain, France and Italy, in collaboration with PharmaMar (MSE:PHM), reported that have presented the results of the metastatic patient group cohort from the single-arm, phase II multicenter study of trabectedin in combination with low-dose radiation therapy for the treatment of Soft Tissue Sarcoma (STS) (Press release, PharmaMar, SEP 30, 2019, View Source [SID1234539935]). The results were presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, which is being held from September 27th to October 1st in Barcelona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study, led by Dr. Martín Broto, oncologist at the Virgen del Rocío University Hospital in Seville (Spain), has reached its primary endpoint of Overall Response Rate (ORR), with 55.6% of responses to the treatment.

Trabectedin in combination with a low-dose of radiotherapy has shown relevant activity in a wide range of soft tissue sarcoma types in patients with advanced metastatic disease, giving other therapeutic options for tumor reduction beyond the first line of treatment.

In addition, this combination has shown a significant impact on Progression Free Survival (PFS) and Overall Survival (OS) in patients with advanced disease who have received a median of two previous lines of treatment. The six-month median for PFS was 75%, while the six-month median for OS was reached by 86% of patients.

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.